Asthma – pharma.markets

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

19/11/2020 MaP 0

• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149)

06/06/2020 MaP 0

….versus a free combination of two existing inhaled treatments in uncontrolled asthma • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a […]